Tempus AI

TEM
Application

AI-enabled diagnostics and clinical data company: genomic and pathology testing for oncology, cardiology and hereditary disease, plus a de-identified real-world dataset licensed to drug developers.

Total funding—
Market cap$12.4B
Employees3,800
Founded2015
HeadquartersChicago, USA
StatusPublic
tempus.com

Products

Selected offerings — the AI products recorded here, not the vendor's full catalogue.

Similar products 31

No sourced competitor yet: no filing, vendor document or measured-market report read so far names a rival for this company, so none is asserted. The companies below are the closest by what their products do.

How this list is ranked ↗

Siemens HealthineersPublicTempus ECG-AF and Deep Resolve do comparable work on medical imaging analysis; both also serve buyers who need to document a clinical encounter; Siemens Healthineers's scale not recorded.2 of 4 capabilitiesShared product typeCompareAidocPrivate · $500M raisedTempus ECG-AF and Aidoc aiOS do comparable work on medical imaging analysis; both also serve buyers who need to document a clinical encounter; similar scale (private).1 of 4 capabilitiesShared product typeCompareInsilico MedicinePublic · $4.3BTempus Lens and inClinico do comparable work on drug discovery; smaller scale (public).3 of 4 capabilitiesShared product typeSmaller scaleCompareOwkinPrivate · $304.1M raisedTempus Lens and BiomarkerPlus do comparable work on drug discovery; similar scale (private); ships AI agent and data service rather than the same layer.2 of 4 capabilitiesDifferent layerCompareChai DiscoveryPrivate · $3.8BTempus Lens and Chai Discovery platform do comparable work on drug discovery; smaller scale (private); ships platform rather than the same layer.1 of 4 capabilitiesDifferent layerSmaller scaleCompareCradlePrivate · $103M raisedTempus Lens and Cradle do comparable work on drug discovery; similar scale (private); ships platform rather than the same layer.1 of 4 capabilitiesDifferent layerCompareIsomorphic LabsPrivate · $2.7B raisedTempus Lens and Drug Design Engine do comparable work on drug discovery; similar scale (private); ships platform rather than the same layer.1 of 4 capabilitiesDifferent layerCompareRecursion PharmaceuticalsPublic · $1.9BTempus Lens and Recursion OS do comparable work on drug discovery; smaller scale (public); ships platform rather than the same layer.1 of 4 capabilitiesDifferent layerSmaller scaleCompareAmbience HealthcarePrivate · $1.3BTempus ECG-AF and Ambience both serve buyers who need to document a clinical encounter; smaller scale (private).Shared product typeSmaller scaleCompareAbridgePrivate · $5.3BTempus ECG-AF and Care Signals both serve buyers who need to document a clinical encounter; smaller scale (private).Shared product typeSmaller scaleCompareWaivPrivate · $35M raisedOverlaps on data analysis; similar scale (private); ships data service and platform rather than the same layer.1 of 4 capabilitiesDifferent layerCompareGoogle DeepMindAcquiredTempus Lens and AlphaFold Server do comparable work on drug discovery; Google DeepMind is acquired, with no independent scale.1 of 4 capabilitiesShared product typeCompareEncordPrivateTempus ECG-AF and Encord do comparable work on medical imaging analysis; Encord's scale not recorded.3 of 4 capabilitiesShared product typeCompareHuawei CloudPrivateTempus Lens and EIHealth do comparable work on drug discovery; Huawei Cloud's scale not recorded.3 of 4 capabilitiesShared product typeCompareOraclePublic · $454.4BTempus ECG-AF and Oracle Health Clinical AI Agent both serve buyers who need to document a clinical encounter; larger scale (public).2 of 4 capabilitiesShared product typeLarger scaleCompareAmazonPublic · $2.8TOverlaps on agent orchestration and data analysis; larger scale (public).2 of 4 capabilitiesShared product typeLarger scaleCompareMicrosoftPublic · $3.7TTempus ECG-AF and Microsoft Dragon Copilot both serve buyers who need to document a clinical encounter; larger scale (public).2 of 4 capabilitiesShared product typeLarger scaleCompareAlphaSensePrivate · $7.5BOverlaps on data analysis; similar scale (private).1 of 4 capabilitiesShared product typeCompareSchneider ElectricPublic · $200.4BOverlaps on data analysis; larger scale (public).1 of 4 capabilitiesShared product typeLarger scaleCompareCopy.aiAcquired ($13.9M deal)Overlaps on agent orchestration and data analysis; Copy.ai is acquired, with no independent scale.2 of 4 capabilitiesShared product typeCompareCrestaPrivate · $1.6BOverlaps on agent orchestration and data analysis; smaller scale (private).2 of 4 capabilitiesShared product typeSmaller scaleCompareMoveworksAcquiredOverlaps on agent orchestration and data analysis; Moveworks is acquired, with no independent scale.2 of 4 capabilitiesShared product typeCompareSalesforcePublic · $196.1BOverlaps on agent orchestration and data analysis; larger scale (public).2 of 4 capabilitiesShared product typeLarger scaleCompareCanvaPrivate · $42BOverlaps on data analysis; larger scale (private).1 of 4 capabilitiesShared product typeLarger scaleCompareGenesysPrivateOverlaps on agent orchestration and data analysis; smaller scale (private).2 of 4 capabilitiesShared product typeCompareWritesonicPrivateOverlaps on data analysis; Writesonic's scale not recorded.1 of 4 capabilitiesShared product typeComparePresightPublic · $5.6BOverlaps on agent orchestration and data analysis; smaller scale (public).2 of 4 capabilitiesShared product typeSmaller scaleCompareNiCEPublic · $6.5BOverlaps on agent orchestration and data analysis; similar scale (public).2 of 4 capabilitiesShared product typeCompareKrispPrivateOverlaps on data analysis; Krisp's scale not recorded.1 of 4 capabilitiesShared product typeComparePalantirPublic · $426.5BOverlaps on agent orchestration and data analysis; larger scale (public); ships infrastructure service and platform rather than the same layer.2 of 4 capabilitiesDifferent layerLarger scaleCompareInvisible TechnologiesPrivate · $144M raisedOverlaps on agent orchestration and data analysis; similar scale (private).2 of 4 capabilitiesShared product typeCompare

Closest alternatives are pairs a vendor page itself compares. Similar products are matched from what each product does; nothing in that group is asserted as a rivalry.

Sources

Market cap

Third-party database · 27 Aug 2026

Refreshed against the listing's own page.

Employees

Regulatory filing · 31 Dec 2025

Tempus AI, Inc. Form 10-K (Item 1, Human Capital), SEC, filed 2026-02-24, for the period ended 2025-12-31. Filing states: "As of December 31, 2025, we had more than 3,800 employees." CIK 1717115.

Founded

Wikipedia · 27 Aug 2026

Wikipedia infobox "founded" field, read 2026-08-27.

Revenue (TTM)

Regulatory filing · 30 Jun 2026

Trailing twelve months to 2026-06-30, added from two filings: FY2025 total net revenue $1,271,789K (10-K) - six months to 2025-06-30 $570,372K + six months to 2026-06-30 $730,602K (Q2 2026 10-Q filed 2026-07-30: "Total net revenue $ 382,486 $ 314,635 $ 730,602 $ 570,372") = $1,432,019K. Neither filing states the TTM figure itself.

Description

Regulatory filing · 24 Feb 2026

FY2025 10-K, Item 1: Tempus is "one of the largest sequencers of cancer patients, and patients with other diseases, in the United States"; cardiology through Tempus Next ("Around 150 hospitals nationwide are currently powered by Tempus Next"), hereditary testing through Ambry.

Open Tempus AI in the directory

Something wrong here? Send a correction — quote this company id: tempus-ai.